Ken Fisher Eagle Pharmaceuticals, Inc. Transaction History

Fisher Asset Management, LLC

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	BUY	$41.26 - $51.35 $404,348 - $503,230	9,800 Added 69.68%	23,864 $1.06 Million
Q1 2022 May 05, 2022	BUY	$44.58 - $52.6 $200,922 - $237,068	4,507 Added 47.16%	14,064 $696,000
Q2 2021 Jul 27, 2021	BUY	$36.86 - $44.5 $106,304 - $128,338	2,884 Added 43.22%	9,557 $409,000
Q1 2021 Apr 27, 2021	SELL	$40.32 - $50.97 $94,026 - $118,862	-2,332 Reduced 25.9%	6,673 $279,000
Q4 2020 Jan 29, 2021	SELL	$41.72 - $51.34 $1,293 - $1,591	-31 Reduced 0.34%	9,005 $419,000
Q3 2020 Nov 10, 2020	SELL	$37.02 - $51.28 $196,206 - $271,784	-5,300 Reduced 36.97%	9,036 $384,000
Q4 2019 Feb 12, 2020	SELL	$54.32 - $64.31 $190,500 - $225,535	-3,507 Reduced 19.65%	14,336 $861,000
Q2 2019 Jul 30, 2019	SELL	$46.61 - $58.45 $4,241 - $5,318	-91 Reduced 0.51%	17,843 $993,000
Q1 2019 Apr 22, 2019	BUY	$38.66 - $51.82 $347 - $466	9 Added 0.05%	17,934 $905,000
Q3 2018 Oct 24, 2018	SELL	$66.65 - $83.86 $188,419 - $237,072	-2,827 Reduced 13.62%	17,925 $1.24 Million
Q2 2018 Jul 09, 2018	SELL	$51.25 - $76.62 $462,890 - $692,031	-9,032 Reduced 30.33%	20,752 $1.57 Million
Q1 2018 May 11, 2018	SELL	$52.16 - $66.86 $662,171 - $848,787	-12,695 Reduced 29.89%	29,784 $1.57 Million
Q1 2018 Apr 19, 2018	BUY	$52.16 - $66.86 $662,171 - $848,787	12,695 Added 42.62%	42,479 $2.24 Million
Q4 2017 Jan 24, 2018	BUY	$49.6 - $60.87 $290,804 - $356,880	5,863 Added 24.51%	29,784 $1.59 Million
Q3 2017 Oct 17, 2017	BUY	$46.62 - $60.36 $1.12 Million - $1.44 Million	23,921	23,921 $1.43 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Fisher Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Fisher Asset Management, LLC and Ken Fisher with notifications on news.